Doximity Inc - Class A
Q3 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: −2.07%.
Did DOCS Beat Earnings? Q3 2026 Results
Doximity delivered a solid fiscal Q3 2026 beat on both top and bottom lines, only to see shares tumble after its forward guidance fell short of Wall Street's expectations. Revenue rose 9.8% year-over-year to $185.05 million, edging past the $181.56 million consensus by 1.93%, while non-GAAP diluted EPS of $0.46 beat the $0.4471 estimate by 2.89%. The headline driver was accelerating platform engagement: the company's newsfeed surpassed 1 million quarterly active prescribers, workflow products hit a record 720,000 users, and <a href="https://247wallst.com/investing/2026/02/24/ai-momentum-propels-digitalocean-past-estimates-with-150-arr-surge/">AI product adoption</a> drew over 300,000 users — a foundation management sees as critical for future monetization. Adjusted EBITDA grew 9% to $111.40 million, holding a robust 60.2% margin, though GAAP net income declined to $61.56 million amid a 54% surge in R&D spending and stock-based compensation that nearly doubled year-over-year. Looking ahead, Doximity guided fiscal Q4 revenue of $143 million to $144 million — a seasonally lighter quarter — and updated full-year fiscal 2026 revenue guidance to a range of $642.50 million to $643.50 million.
- Record platform engagement with over 1 million quarterly active prescribers on the newsfeed
- Workflow products reached 720,000 users, a record quarter-over-quarter jump
- AI product adoption surpassed 300,000 users
- 10% year-over-year revenue growth
“We're proud to deliver another quarter of strong profits and record engagement. Our newsfeed had more than 1 million quarterly active prescribers, our workflow products had 720,000 (a record QoQ jump), and our nascent AI products had over 300,000. In short, the addition of AI features across our platform has made us more useful than ever.”
Doximity CEO, on the earnings call
Forward Guidance & Outlook
For fiscal Q4 2026 (ending March 31, 2026), Doximity guided revenue of $143 million to $144 million and adjusted EBITDA of $63.5 million to $64.5 million. For the full fiscal year 2026, the company updated guidance to revenue of $642.5 million to $643.5 million and adjusted EBITDA of $355.5 million to $356.5 million.
DOCS YoY Financials
DOCS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.